Stock Analysis

Discover Archean Chemical Industries And 2 Other Stocks Trading Below Intrinsic Value Estimates On The Indian Exchange

NSEI:BLUEJET
Source: Shutterstock

The Indian market increased by 1.0% over the last week and is up 45% over the past 12 months, with earnings forecast to grow by 17% annually. In this thriving environment, identifying stocks trading below their intrinsic value can present significant opportunities for investors looking to capitalize on potential growth.

Top 10 Undervalued Stocks Based On Cash Flows In India

NameCurrent PriceFair Value (Est)Discount (Est)
Everest Kanto Cylinder (NSEI:EKC)₹183.23₹306.0040.1%
Apollo Pipes (BSE:531761)₹592.05₹1146.2248.3%
Krsnaa Diagnostics (NSEI:KRSNAA)₹706.70₹1165.3339.4%
Prataap Snacks (NSEI:DIAMONDYD)₹838.60₹1509.7944.5%
Venus Pipes and Tubes (NSEI:VENUSPIPES)₹2397.60₹4385.1145.3%
IOL Chemicals and Pharmaceuticals (BSE:524164)₹436.05₹762.3242.8%
Updater Services (NSEI:UDS)₹369.25₹619.8140.4%
RITES (NSEI:RITES)₹650.25₹1035.6037.2%
Artemis Medicare Services (NSEI:ARTEMISMED)₹274.35₹445.1538.4%
Manorama Industries (BSE:541974)₹836.80₹1665.5149.8%

Click here to see the full list of 31 stocks from our Undervalued Indian Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Archean Chemical Industries (NSEI:ACI)

Overview: Archean Chemical Industries Limited manufactures and sells specialty marine chemicals in India and internationally, with a market cap of ₹87.34 billion.

Operations: Archean Chemical Industries Limited generates revenue primarily from its Marine Chemicals segment, amounting to ₹11.99 billion.

Estimated Discount To Fair Value: 10.5%

Archean Chemical Industries appears undervalued based on cash flows, trading at ₹707.80, below the estimated fair value of ₹791.13. Despite recent penalties totaling over INR 7 million for GST issues and a decline in Q1 earnings to INR 448.57 million from INR 938.56 million last year, its revenue is forecasted to grow at 28.2% annually, outpacing the Indian market's growth rate of 10%. Earnings are also expected to rise significantly by 33.7% per year over the next three years, with a high return on equity forecasted at 24.4%.

NSEI:ACI Discounted Cash Flow as at Sep 2024
NSEI:ACI Discounted Cash Flow as at Sep 2024

Blue Jet Healthcare (NSEI:BLUEJET)

Overview: Blue Jet Healthcare Limited manufactures and sells pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products, with a market cap of ₹80.64 billion.

Operations: The company's revenue segment primarily consists of the manufacturing and sale of pharmaceutical and healthcare products, generating ₹6.95 billion.

Estimated Discount To Fair Value: 14.8%

Blue Jet Healthcare Limited, trading at ₹464.85, is undervalued based on cash flows with an estimated fair value of ₹545.78. Despite a recent decline in Q1 earnings to INR 377.77 million from INR 441.21 million last year, the company has expanded its production capacity and forecasts significant growth in earnings (25.6% annually) and revenue (25.1% annually), outpacing the Indian market's growth rates of 17% and 10%, respectively, with a high return on equity projected at 26%.

NSEI:BLUEJET Discounted Cash Flow as at Sep 2024
NSEI:BLUEJET Discounted Cash Flow as at Sep 2024

Updater Services (NSEI:UDS)

Overview: Updater Services Limited operates an integrated business services platform in India with a market cap of ₹24.72 billion.

Operations: Updater Services Limited generates revenue from Business Support Services amounting to ₹8.67 billion and Integrated Facility Management Services totaling ₹16.99 billion.

Estimated Discount To Fair Value: 40.4%

Updater Services Limited, trading at ₹369.25, is significantly undervalued based on cash flows with an estimated fair value of ₹619.81. Despite recent regulatory actions totaling over INR 14 million, the company reported strong Q1 earnings growth to INR 253.62 million from INR 129.06 million last year and expects annual profit growth of 36.1%. Revenue is forecasted to grow at 14.8% per year, outpacing the Indian market's average growth rate of 10%.

NSEI:UDS Discounted Cash Flow as at Sep 2024
NSEI:UDS Discounted Cash Flow as at Sep 2024

Where To Now?

Seeking Other Investments?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Blue Jet Healthcare might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com